114  Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease. Issue 6 (27th May 2022)

• Record Type: Journal Article
• Authors: Penner, K; Giovannoni, G; Cree, BAC; Fox, RJ; Bar-ors, A; Gold, R; Vermesch, P; Piani-Meier, D; Ritter, S
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 93:Issue 6(2022)
• Page Start: A136
• Page End: A136
• Publication Date: 2022-05-27
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2022-ABN.439
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Background: Siponimod significantly reduced the relative risk of 3-month (m) confirmed disability progression (CDP) by 21% and 6mCDP by 26% versus placebo in the EXPAND core study and showed significant benefits on cognitive processing speed (CPS) using the Symbol Digit Modalities Test (SDMT). Objectives: To evaluate the effect of siponimod on CPS in active (aSPMS) and non-active (naSPMS) patients from EXPAND core study. Methods: This subgroup analysis included aSPMS patients (siponimod, n=516; placebo, n=263) and naSPMS patients (siponimod, n=557; placebo, n=270). Change in SDMT score; time to 6m confirmed ≥4-points cognitive worsening/improvement (6mCW/6mCI) on SDMT and the proportion of patients with worsened, stable and improved SDMT scores at M24 were analysed. Results: Change in SDMT (95% Cl) versus placebo from baseline to M24 in aSPMS and naSPMS groups was 2.34 (0.66; 4.02) and 2.44 (0.67; 4.22), respectively, consistent with overall EXPAND core population. In aSPMS patients, siponimod reduced risk of 6mCW by 27% (p=0.06) and improved chances of 6mCI by 62% (p=0.007) versus placebo. Corresponding values in the naSPMS group were: 6mCW, 24% (p=ns) and 6mCI, 19% (p=ns). Conclusions: Siponimod was associated with relevant benefits in CPS as measured by change in SDMT in patients with active and non-active SPMS. teresa: [e-mail] 82